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unobserved selectivity, a condition not satisﬁed in many
retrospective healthcare studies, especially those based on
administrative claims databases.
PMD5
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OBJECTIVES: The same standards should apply for 
measuring patient reported outcomes (PRO) as for any
clinical measure used for an effectiveness claim. Yet, dis-
crepancies between the number of submissions and the
number of PRO claims granted illustrate how difﬁcult it
is to demonstrate the “substantial evidence” required by
authorities. Reporting PRO data separately from the clin-
ical data makes reviewing PRO claims difﬁcult. However,
International Conference Harmonization (ICH) guide-
lines provide no standard location for PRO measurement
information. Better integration of PRO data in clinical
reports and standardized documentation of PRO mea-
sures would improve the reviewing process and enhance
the likelihood of securing claims. We will present the
value of implementing a standardized approach to docu-
menting PRO measures in regulatory submission reports.
METHODS: Our recommendations are based on ICH
guidelines and the ERIQA and PRO Harmonization
group recommendations. While current ICH report
guidelines provide no headings for documenting back-
ground information on PRO measures, appropriate head-
ings can be added to report PRO methods and ﬁndings
as part of the primary clinical trial report without 
modifying the ICH numbering system. However, the
questionnaire development and validation relevant to 
the condition and treatment considered are better located
in supporting appendices as are reviews of literature 
documenting the use and interpretation of data collected
with it. RESULTS: These appendices should include evi-
dence of the clinical signiﬁcance of differences to help
reviewers familiarize themselves with the instrument.
CONCLUSION: Better integration of PRO in clinical
study report guidelines and the development of a speciﬁc
system for standardized documentation of PRO measures
will enhance transparency and acceptance of PRO data,
and thereby increase the acceptance by decision-makers
of effectiveness claims based on PRO.
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OBJECTIVES: To establish clinical meaningfulness of
effect sizes and validate measures of patient-reported out-
comes (PROs), it is important to understand the effect of
acute clinical events on PROs. When PROs are measured
before and after an acute event, there are several options
for measuring change. This example illustrates the beneﬁt
of adjusting estimates of change for patients’ pre-event
trajectories. METHODS: To determine the effect of
pathologic fractures (PF) on PROs, we used data from a
clinical trial of zoledronic acid versus placebo in patients
with prostate cancer (N = 643). Only patients who expe-
rienced a PF were included in this analysis (n = 76). 
For illustrative purposes, the Functional Assessment of
Cancer Therapy-General (FACT-G) total score was com-
pared before and after each patient’s ﬁrst PF using two
methods: 1) estimate simple mean change from pre-PF
value to post-PF value and perform a paired t-test; and
2) use a linear mixed effects model to analyze all time
points from baseline to the ﬁrst time point after the PF,
with a dummy variable indicating the pre-PF (0) and post-
PF (1) status. The ﬁxed-effect for the dummy variable is
the trajectory-adjusted mean change (TAMC). (Note:
analyses not reported here showed signiﬁcant effects of
PF on three of the four FACT subscales). RESULTS: The
simple mean change was -4.03 (SD = 13.57), which was
signiﬁcant by a paired t-test (p = 0.04). The TAMC,
however, was -2.00 (95% CI = -5.53, 1.52), and was not
statistically signiﬁcant (p = 0.26). CONCLUSIONS: In
assessing the impact of acute events on PROs, simple 
pre-post comparisons may misestimate effect size and/or
statistical signiﬁcance. The mixed-effects model presented
here more accurately assesses changes in PROs by adjust-
ing for the pre-event trajectory due to prostate cancer
with bone metastases, isolating the change in PROs
attributable to the acute clinical event.
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OBJECTIVES: The objective of this paper is to deter-
mine the congruence of self-report measures of medica-
tion adherence with other measures of adherence.
METHODS: A literature search was conducted across
1978–2002. MEDLINE, PsychInfo, IPA and ISI databases
were used to identify studies that met the following inclu-
sion criteria: 1) study included at least one self-report
measure and one non-self-report measure of adherence;
2) data were reported that would allow a comparison of
the measures (e.g., individual scores or a correlation/con-
cordance statistic); and 3) the report was in English. The
studies were categorized by type of self-report adherence
measure (questionnaire, diary, interview) and by type 
of non-self-report method (administrative claims, pill
count/canister weight, biological assay, electronic mea-
